

Nityam Rathi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5611054/publications.pdf>

Version: 2024-02-01

29
papers

262
citations

1040056

9
h-index

996975

15
g-index

29
all docs

29
docs citations

29
times ranked

357
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 365-368.	1.9	38
2	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	3.7	33
3	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.	5.4	29
4	Every decade counts: a narrative review of functional recovery after partial nephrectomy. <i>BJU International</i> , 2023, 131, 165-172.	2.5	25
5	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	3.7	19
6	Predicting GFR after radical nephrectomy: the importance of split renal function. <i>World Journal of Urology</i> , 2022, 40, 1011-1018.	2.2	16
7	<p>Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3741-3749.	1.9	15
8	Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 149-154.	1.0	14
9	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. <i>Drugs</i> , 2021, 81, 191-206.	10.9	11
10	Assessing the Structures and Interactions of $\hat{1}^3$ D-Crystallin Deamidation Variants. <i>Structure</i> , 2021, 29, 284-291.e3.	3.3	10
11	Split Renal Function Is Fundamentally Important for Predicting Functional Recovery After Radical Nephrectomy. <i>European Urology Open Science</i> , 2022, 40, 112-116.	0.4	10
12	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4807-4813.	7.0	9
13	Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. <i>Oncologist</i> , 2021, 26, 751-760.	3.7	9
14	Partial Versus Radical Nephrectomy: Complexity of Decision-Making and Utility of AUA Guidelines. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 501-509.	1.9	5
15	Optimizing prediction of new-baseline glomerular filtration rate after radical nephrectomy: are algorithms really necessary?. <i>International Urology and Nephrology</i> , 2022, 54, 2537-2545.	1.4	4
16	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 639-639.	1.6	3
17	The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, E1-E6.	1.0	3
18	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 724-726.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset.. Journal of Clinical Oncology, 2020, 38, 5537-5537.	1.6	2
20	DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). World Journal of Oncology, 2018, 9, 119-122.	1.5	2
21	Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 580-580.	1.6	1
22	Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, 681-681.	1.6	1
23	Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.. Journal of Clinical Oncology, 2020, 38, 5077-5077.	1.6	1
24	Independent assessment of TP53 and PTEN as predictors of response to enzalutamide (ENZ) or abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 351-351.	1.6	0
25	A Genome-wide association study of metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, 160-160.	1.6	0
26	Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2019, 37, 5043-5043.	1.6	0
27	Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile.. Journal of Clinical Oncology, 2020, 38, e17596-e17596.	1.6	0
28	Identification of genomic aberrations associated with overall survival in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2020, 38, 745-745.	1.6	0
29	Association of serum iron and response to immune checkpoint inhibitors (ICIs) in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2020, 38, 723-723.	1.6	0